|Day Low/High||158.50 / 161.50|
|52 Wk Low/High||123.73 / 192.15|
A look at three names to consider in the biotech and biopharma space.
Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.
Data and industry conferences will likely be catalysts for shares in the space.
U.S. equity futures gave back earlier gains Monday even as investor concern over prolonged military action in Syria faded following weekend missile strikes in reaction to an alleged chemicals weapons attack last week in the city of Douma.
Shire will sell its oncology business to France's Servier for around $2.4 billion as it contemplates a possible $50 billion takeover from Japan's Takeda Pharmaceutical Co.
Oil remained near a three-year high despite falling back slightly on Thursday.
China on Friday said it would counter Trump's proposed new tariffs 'to the end, and at any cost'
Wall Street is also expected to start the day in positive territory on Thursday after tumultuous trading on Wednesday.
Better-than-expected earnings will help soothe market jitters in the second quarter.
M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.
Strength in the morning yields to weakness in the afternoon session as stocks are sold off Wednesday.
Shire Pharmaceuticals shares hit a year-to-date high Wednesday after Japan's biggest drugmaker, Takeda, confirmed it may make a takeover approach for the U.K.-listed group.
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
The most recent short interest data has been released for the 12/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
Roche sees success in trials for its cancer and hemophilia drugs
The markets' climb hits a detour at the end of the week. In the portfolio, after adding five names to the bullpen, we promoted one of them to the portfolio.
Cooperman founded Omega Advisers in 1991.
Evercore ISI analyst Josh Schimmer is bullish on biotech.
A number of biotech-related stocks were down pre-market after announcing plans for public offerings.
The drug would be the first such treatment in Europe.
The labor market goes under inspection and Apple releases its earnings report.
Shire is also said to have hired its own defense advisers to ward off low bids.
Here are the activist investor's next potential targets.
The activist will gain $320 million on the sale, which suggests that the fund either doesn't believe a higher bidder is coming or that they need the cash.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
Shire, Bellicum Pharmaceuticals and Organovo Holdings were among the biotech stock movers in premarket trading on June 22.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.